Former Boston Scientific exec joins InspireMD board
Michael Berman joined the board of directors at InspireMD (OTC:NSPR) after a stint among medtech startups and serving as Boston Scientific’s (NYSE:BSX) senior VP. Berman served as the president of Scimed and oversaw the merger with Boston Scientific in 1995.
"Mike brings a wealth of firsthand experience in building global medical device businesses. Further, having previously worked directly with and for Mike, I know his contributions to growing our business will be both immediate and impactful," said Alan Milinazzo, InspireMD’s CEO.
Berman also sits on the board of 8 other medical device companies.
FDA searching for a few good committee members
In an announcement sent out on February 7, the FDA asked for nominations for voting members of a variety of public advisory boards and committees. The agency put out a request for qualified candidates to fill spots on the Device Good Manufacturing Practice Advisory Committee, the Medical Devices Advisory Committee, the National Mammography Quality Assurance Advisory Committee, and the Technical Electronic Products Radiation Safety Standards Committee.
Digirad shuffles its board of directors
R. King Nelson and Gerhard Burbach both resigned from the board of directors at Digirad (NSDQ:DRAD). In the wake of the paid of resignations, the company decided to shrink the board from 8 to 6 members. Nelson was the former chairman of the board, and will be succeeded by Jeffrey Eberwein, effective immediately. Burbach was formerly president and CEO of Digirad, and has served on the board since 2004.
Stereotaxis appoints interim CFO in wake of resignation
Stereotaxis (NSDQ:STXS) CFO Sam Duggan put in his 2 weeks’ notice to take a new gig at an unnamed larger company in the private sector. Martin Stammer, the current VP and controller, will take over as interim CFO, beginning February 22, at which time Stammer will also be promoted to principal accounting officer.
"Sam joined the company during a difficult period and has been instrumental in significantly reducing our cost structure and improving our financial performance," said CEO Michael Kaminski in a statement. "We will miss his thoughtful counsel and collaborative leadership but wish him great success in this new opportunity at a much larger company."